ArticleViruses2025
A Highly Specific Antibody-Based Assay for
Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Development of a Rapid and Sensitive AlphaLISA-Based Assay for Lassa Virus Glycoprotein Detection.Pathogens (Basel, Switzerland) · 2026Article
- Leveraging single B cell antibody platforms to develop countermeasures against animal viral diseases: recent advances and future perspectives.Frontiers in veterinary science · 2026Review
- Innovations, Applications, and Future Trends in Veterinary Diagnostic Technologies.Transboundary and emerging diseases · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Nipah virus (NiV) is an emerging zoonotic pathogen whose surface glycoprotein (G)-mediated host cell invasion mechanism leads to fatal encephalitis in infected patients (case fatality rate 40-75%). Given the limitations of existing diagnostic technologies, such as low sensitivity and prolonged processing times, we prepared an anti-NiV-G monoclonal antibody to establish a novel Amplified Luminescent Proximity Homogeneous Assay (AlphaLISA) detection system. Firstly, five high-affinity anti-NiV-G monoclonal antibodies were screened from the spleens of immunized mice by flow cytometry-single-cell cloning technology. The reaction system was further optimized, and the optimal dilution ratio of antibody-conjugated receptor microspheres, biotinylated antibodies, and donor microspheres was screened, and the AlphaLISA detection platform was successfully constructed. The detection sensitivity of NiV-G protein was 0.024 ng/mL (41.7 times higher than that of conventional ELISA), the coefficient of variation was <9.5%, and the repetition was good. It showed good specificity in the detection of 5 zoonotic viruses, including Japanese encephalitis virus and Zika virus. At the same time, this method is less disturbed by human serum, and the detection time is less than 30 min, showing a good clinical application prospect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.